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Ensuring the ﬁtness of the pluripotent cells that will contribute to future development is
important both for the integrity of the germline and for proper embryogenesis. Consequently,
it is becoming increasingly apparent that pluripotent cells can compare their ﬁtness levels and
signal the elimination of those cells that are less ﬁt than their neighbours. In mammals the
nature of the pathways that communicate ﬁtness remain largely unknown. Here we identify
that in the early mouse embryo and upon exit from naive pluripotency, the confrontation of
cells with different ﬁtness levels leads to an inhibition of mTOR signalling in the less ﬁt cell
type, causing its elimination. We show that during this process, p53 acts upstream of mTOR
and is required to repress its activity. Finally, we demonstrate that during normal develop-
ment around 35% of cells are eliminated by this pathway, highlighting the importance of this
mechanism for embryonic development.
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From the earliest embryonic divisions until the death of theorganism, cells are subjected to a remarkable array ofpressures that will compromise their ﬁtness. Cell competi-
tion is a quality control mechanism that allows the comparison of
ﬁtness levels between cells and results in the elimination of those
which are viable but less ﬁt than their neighbours. The process
has been primarily studied in Drosophila, where it is thought to
play beneﬁcial roles in the optimisation of tissue ﬁtness during
embryonic development1, the regulation of organ size2,3 and the
maintenance of adult tissue homoeostasis during ageing4. In ﬂies,
cell competition can also be exploited by cancer cells to eliminate
the surrounding wild-type tissue, both to make space for their
expansion and fuel their transformation5–7.
During the early stages of mammalian embryonic differentia-
tion, a wide range of cellular changes take place, including a
dramatic increase in the proliferation rate and a rewiring of the
transcriptional, epigenetic, metabolic and signalling networks.
The dimension of these changes and the requirement for their
timing to be carefully orchestrated8 provides a signiﬁcant
potential for the emergence of aberrant cells that cannot perform
these changes efﬁciently and need to be removed before speciﬁ-
cation of the germline. Consequently, the onset of gastrulation in
mouse is accompanied by a wave of cell death as the epiblast
becomes hypersensitive to death signals9–11.
Cell competition has been suggested to be one of the quality
control mechanisms that ensures ﬁtness selection in the early
mouse embryo12,13. We have shown that during the onset of
differentiation, cell competition eliminates defective or mis-
patterned cells speciﬁcally when they are surrounded by ﬁtter
cells12. Similarly, cells with lower levels of c-Myc than their
neighbours12–14 or higher levels of p5315 are also eliminated by
cell competition in the mouse embryo. Recently in mouse, Myc-
induced competition has been suggested as a mechanism to
safeguard pluripotency16, as the low c-Myc cells eliminated by cell
competition were found to be less pluripotent than their high c-
Myc counterparts. However, although differences in c-Myc and
p53 are recognised by the cell competition machinery as differ-
ences in ﬁtness levels, we do not know what pathways are acti-
vated in the mouse embryo downstream of these triggers
speciﬁcally in a competitive context.
The mechanistic target of rapamycin (mTOR) pathway inte-
grates a variety of extracellular and intracellular signals and
functions to control cell growth and metabolism. The mTOR
complex 1 (mTORC1, hereafter referred to as mTOR) drives
anabolic metabolism in response to positive growth inputs but
activates catabolic pathways during starvation17. Here we report
that mTOR signalling is a key effector of cell competition in the
early mouse embryo, as loss of mTOR signalling is both required
and sufﬁcient for the elimination of defective cells in a compe-
titive environment. We also ﬁnd that the tumour suppressor p53
acts upstream of mTOR during this process, and that elevated
p53 expression not only labels defective cells as less ﬁt than their
neighbours, but also is required for mTOR repression during cell
competition. Together, these observations shed light on the
pathways that regulate competitive ﬁtness during early mouse
development.
Results
mTOR is a readout of competition between pluripotent cells.
Here our aim is to identify the pathways that mediate ﬁtness
selection during early mouse embryogenesis, and speciﬁcally
those that respond to relative ﬁtness levels rather than eliminate
cells with defects that directly affect their viability. For this we use
two different cell models that carry defects that can emerge
during early embryogenesis but are not intrinsically cell-lethal:
mis-patterning18 and karyotypic abnormalities19. The BMP sig-
nalling defective (Bmpr1a−/−) cells are mispatterned when sur-
rounded by other defective cells20, but are eliminated by cell
competition when surrounded by wild-type cells12. Similarly,
tetraploid (4n) cells survive until very late in development or birth
when the whole embryo is tetraploid21–23, but are eliminated by
apoptosis when in chimeras with wild-type cells12. When refer-
ring to these two cell types, we collectively term them as defective
or loser cells. To pursue the molecular mechanisms regulating
their elimination when surrounded by wild-type cells we use a cell
culture system where GFP-labelled defective embryonic stem cells
(ESCs) are either co-cultured with wild-type cells or cultured as
two separate homogeneous populations (separate culture). The
phenotypes present in the co-culture condition, but not in the
separate cultures, are deemed to be speciﬁc of cell competition.
Cells are cultured in serum-free N2B27 media, as this induces
differentiation and triggers cell competition12. In these condi-
tions, defective cells grow normally in separate culture but are
efﬁciently eliminated from day 3 of co-culture (Fig. 1a).
To identify pathways involved in defective cell elimination, we
used microarray proﬁling followed by Ingenuity Pathway
Analysis (IPA), which identiﬁes molecular interactions in omics
data. Analysis of the transcriptome of wild-type and BMP-
defective cells in separate and co-culture conditions revealed high
activation Z-scores for mTOR and related pathways speciﬁcally in
the co-culture condition (Supplementary Fig. 1A–C),
suggesting that mTOR may regulate cell competition in the early
mouse embryo. To test this hypothesis, we compared mTOR
signalling in wild-type and defective cells in separate and
co-culture conditions. We observed by immunoﬂuorescence
and ﬂow cytometry analysis that ribosomal protein S6 (S6)
phosphorylation, a key signalling readout of this pathway, was
decreased in both BMP-defective and 4n cells speciﬁcally when
they were co-cultured with wild-type cells (Fig. 1b–h and
Supplementary Fig. 1D). This starkly contrasted with the robust
levels of mTOR activation that control cells showed in separate
and co-culture. Furthermore, when cell competition was inhibited
by maintaining cells in the naive pluripotent state12, we observed
that mTOR activation in co-culture was similar in defective and
wild-type cells (Supplementary Fig. 1E, F), indicating that the loss
of mTOR signalling occurs speciﬁcally during competitive
interactions. Thus, in two unrelated cell competition models,
the confrontation with ﬁtter cells leads defective cells to
downregulate mTOR pathway activity.
Reduced mTOR signalling induces less-ﬁt cell elimination.
mTOR plays many roles in the regulation of growth17 and is
required for early post-implantation mouse development24,25. We
therefore asked if the decrease in mTOR activity observed in loser
cells is the reason for their elimination. We have previously
shown that caspase inhibition rescues loser cell elimination dur-
ing cell competition12. We found that preventing apoptosis also
led to an accumulation of cells with low pS6 staining (Fig. 2a–c),
suggesting these would otherwise be eliminated by cell competi-
tion. To test whether inhibition of the mTOR pathway is sufﬁ-
cient to induce cell death, we treated differentiating cells with the
mTOR inhibitor rapamycin and assessed cell viability. Within 6 h,
rapamycin markedly increased the activation of apoptotic mar-
kers and by 24 h it led to a 50% reduction in cell numbers
(Fig. 2d–f). The cell counts could be rescued by caspase inhibi-
tion, indicating that decreasing mTOR activity during ESC dif-
ferentiation induces death (Fig. 2d), a ﬁnding consistent with the
requirement for mTOR signalling for post-implantation embryo
survival24,25. Our observations were not due to changes in
mTORC2 pathway activation, as levels of pAKTT473, a direct
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Fig. 1 Reduced levels of mTOR pathway activity in defective cells during cell competition. a Growth curves of wild-type and Bmpr1a−/− cells over 7 days in
separate and co-culture. b Phospho-S6S240/244 levels in wild-type and Bmpr1a−/− cells cultured separately and together were assessed by
immunoﬂuorescence analysis and quantiﬁed (c). Scale bar= 200 μm. d Total (S6) and phospho-S6 (pS6) levels in wild-type and Bmpr1a−/− cultured
separately and together were assessed by ﬂow cytometry, and the median ﬂuorescence of Bmpr1a−/−/wild-type cells was compared in separate and co-
culture over the ﬁrst three days in competition (e). f Levels of pS6S240/244 in wild-type and tetraploid (4n) cells after three days in competition were
assessed by immunoﬂuorescence. Scale bar= 50 μm. g Levels of pS6S240/244 levels in wild-type and 4n cells after three days in competition were
assessed by ﬂow cytometry and the median ﬂuorescence of 4n/wild-type cells was compared in separate and co-culture at day three days of competition
(h). n > 3; error bars denote standard error of the mean (SEM). **p < 0.01 and *** p < 0.005; unpaired, two-tailed t-test (c, h) or ANOVA and Tukeys post-
hoc test (e)
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target of mTORC2, were not altered by rapamycin treatment
(Fig. 2e). When naive pluripotent cells were treated with rapa-
mycin no induction of apoptosis was observed (Fig. 2e, f), in
agreement with the recent observations that in these cells low
mTOR induces a diapause-like state26. These results suggest that
the loss of mTOR observed in defective cells during competition
is directly causing their elimination.
mTOR is required for less-ﬁt cell elimination. The above
observations suggest that mTOR repression induces defective cell
elimination, but we also wanted to address if restoring the activity
of this pathway is sufﬁcient to prevent this elimination. For this
we targeted Tsc2 (tuberin), an inhibitor of the mTOR pathway, by
CRISPR mutagenesis. Bmpr1a−/−;Tsc2−/− clones displayed a loss
of TSC2 expression and increased phosphorylation of S6 (Sup-
plementary Fig. 2A). Notably, this increase in mTOR activity
induced by TSC2 inhibition completely rescued Bmpr1a−/−
apoptotic cell elimination during cell competition (Fig. 3a, b).
This was highlighted by the observations that Bmpr1a−/− cell
numbers and apoptosis levels in co-culture were restored to those
levels seen in these cells in separate culture (Fig. 3a). Importantly,
accompanying this rescue of Bmpr1a−/− cell elimination, we
observed a change in the behaviour of the wild-type cells the co-
culture. We found that when wild-type cells were in a competitive
environment with Bmpr1a−/−;Tsc2−/− cells, instead of growing
exponentially they decreased in cell number (Fig. 3b). This
indicates that complete abrogation of TSC2 function makes
Bmpr1a−/− cells more competitive than wild-type cells. In
contrast to this, although partial inhibition of Tsc2 using
shRNAs or siRNAs also rescued Bmpr1a−/− cell elimination
in co-culture, it did not affect wild-type cell numbers
(Supplementary Fig. 2B-F and I), suggesting that the level of Tsc2
inhibition determines the competitive ability of a cell.
TSC2 has been described to regulate exit from pluripotency27.
To identify whether mTOR hyperactivation through Tsc2
knockdown was affecting competition through blocking cell
differentiation, we analysed expression of pluripotency markers in
Tsc2-knockdown cells. After three days in N2B27 no differences
were observed compared to controls (Supplementary Fig. 2G–H)
allowing us to exclude this possibility.
To assess whether mTOR is likewise functionally important in
our tetraploid cell competition model we hyper-activated the
pathway in 4n cells. We generated two 4n;Tsc2−/− clones by
CRISPR that maintained their starting tetraploidy (Supplemen-
tary Fig. 3A, B). We observed that deletion of Tsc2 restored
mTOR levels in 4n cells in co-culture (Supplementary Fig. 3C)
and completely rescued their apoptotic elimination by wild-type
cells (Fig. 3c). Again, accompanying this rescue of 4n cell
elimination, we observed that in co-culture, wild-type cells
decreased in cell number (Fig. 3d). Analysis of pluripotency
markers revealed that although 4n-Tsc2 null cells present a delay
in differentiation, they were still capable of exiting the pluripotent
state: at day 3 in N2B27, we observed increased CD31 staining
compared with 4n-GFP-targeted controls but by day 4 pluripo-
tency gene expression was similar to controls (Supplementary
Fig. 3E, F). Therefore, the rescue we observe is independent of the
role of TSC2 in differentiation.
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Fig. 2 Repression of the mTOR pathway triggers cell death in differentiating ESCs. a Schematic of experimental setup whereby cells were cultured
separately and together for two days in N2B27 before being treated with 100 μM caspase inhibitors for 48 h. Cells were then ﬁxed and levels of
pS6S240/244 were assessed. b Levels of pS6S240/244 were assessed by ﬂow cytometry in wild-type and Bmpr1a−/− cells following 48 h treatment with
DMSO or caspase inhibitors (100 uM), and c median ﬂuorescence of Bmpr1a−/− cells was quantiﬁed. dWild-type cells were cultured in N2B27 for 2 days,
treated with mTOR inhibitor rapamycin for 24 h and cell count was assessed following treatment with and without caspase inhibitors. e Wild-type cells
cultured in ESC media, to maintain pluripotency, and N2B27, to initiate differentiation, were treated with rapamycin for 6 h and levels of cell death were
assessed by western blot analysis of cl. caspase-3 and cl. PARP. f Quantiﬁcation of cleaved caspase-3 levels relative to β-actin. Error bars denote SEM.
*p < 0.05, **p < 0.01 and *** p < 0.005; unpaired, two-tailed t-test (c, d) or ANOVA and Tukeys post-hoc test (f)
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The observation that 4n-Tsc2 null cells can affect the growth of
wild-type cells suggests that constitutive activation of mTOR
signalling can make cells into super-competitors (i.e. capable of
eliminating surrounding wild-type cells). To test this possibility in
a diploid background, we deleted Tsc2 by CRISPR in wild-type
cells and performed competition assays with unaltered wild-type
cells. We selected two Tsc2−/− clones with absent levels of TSC2
and hyperactivation of mTOR (Supplementary Fig. 4A). While
these Tsc2−/− cells were able to exit naive pluripotency and grew
at similar rates to wild-type cells in separate culture (Supple-
mentary Fig. 4B-C), they induced the apoptotic elimination of
wild-type cells in co-culture, which showed a doubling in the
proportion of cleaved caspase-3 positive cells at day 4 (Fig. 3e).
Accompanying the elimination of wild-type cells in co-culture,
the Tsc2−/− cells displayed increased growth (Fig. 3f), suggesting
they were undergoing compensatory proliferation. These results
indicate that mTOR is a key regulator of relative ﬁtness levels, as
not only does the loss of activity of this pathway lead to
defective cell elimination, but also increasing mTOR activity is
sufﬁcient to trigger competition and transform cells into super-
competitors.
p53 lies upstream of mTOR during defective cell elimination.
We next looked for factors that could regulate mTOR during
competition. For this we took a systematic approach and mined
our IPA analysis of the transcriptional proﬁles of wild-type and
defective cells for candidates. This study revealed p53, which is
known to repress mTOR signalling28, as the gene with most
enriched targets in defective cells (Supplementary Fig. 5A). Fur-
thermore, in Drosophila, p53 is required for the metabolic
reprogramming of winner cells during cell competition29 and in
MDCK cells, hematopoietic stem cells and mouse embryos an
elevation of p53 is sufﬁcient to confer cells with a selective
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Fig. 3 Constitutive activation of the mTOR pathway in defective cells rescues their elimination during competition. a Fold change in Bmpr1a−/− and
Bmpr1a−/−; Tsc2−/− (two independent clones) cell numbers between d0–d4 and percent of cleaved caspase-3 positive cells at day 4 cells when cultured
alone (separate) or with wild-type cells in N2B27. b Fold change in wild-type cell numbers between d0-d4 when cultured separately or co-cultured with
Bmpr1a−/− or Bmpr1a−/−; Tsc2−/− cells. c Fold change in 4n and 4n; Tsc2−/− (two separate independent clones) cell numbers between d0–d4 and percent
of cleaved of caspase-3 positive cells at day 4 when cultured separately or with wild-type cells in N2B27. d Fold change in wild-type cell numbers between
d0–d4 when cultured separately or co-cultured with 4n or 4n; Tsc2−/− cells. e Fold change in wild-type cell numbers between d0–d4 and percent of
cleaved caspase-3 positive cells at day 4 when cultured separately or co-cultured with Cas9 or Tsc2−/− cells (two independent clones) in N2B27. f Fold
change in Tsc2−/− cell numbers between d0–d5 when cultured separately or co-cultured with wild-type cells. n= 3 for all studies. Error bars denote SEM.
*p < 0.05, **p < 0.01 and *** p < 0.005; ANOVA and Tukeys post-hoc test
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disadvantage15,30,31. We observed that expression of p53 and its
target p21 were increased in both BMP-defective and 4n cells
compared to wild-type cells in both separate and co-culture
conditions (Fig. 4a–c, Supplementary Fig. 5B, C). In Bmpr1a−/−
cells, this increase was not caused by double-strand DNA breaks,
as very low levels of gamma-H2AX staining were observed in
these cells (Supplementary Fig. 5D). These data suggest that
elevated p53 expression is marking defective cells as potential
loser cells.
To test if p53 lies upstream of mTOR, we did three things.
First, we assessed whether p53 represses mTOR signalling in
differentiating ESCs by performing a knockdown of p53 in wild-
type cells using shRNAs and culturing these for three days in
N2B27. We observed that inhibition of p53 resulted in an increase
in mTOR pathway components pS6 and p4E-BP1 (Fig. 4d).
Conversely, we treated wild-type cells with the p53 activator
Nutlin-3a and found that increased expression of p53 leads to a
repression of mTOR signalling activity (Fig. 4e, f). Neither
treatment of cells with rapamycin nor deletion of Tsc2 by CRISPR
affected p53 levels in Bmpr1a−/− cells (Supplementary Fig. 5E-F).
Together, these data suggest that p53 activation can inhibit
mTOR signalling but that the reverse is not the case.
We then analysed if inhibition of p53 can rescue mTOR
levels and defective cell elimination during competition. We
initially reduced p53 levels in Bmpr1a−/− or 4n cells co-
cultured with wild-type cells using siRNAs. In both these cases
we observed a partial restoration of mTOR activation levels and
a rescue of defective cell growth in co-culture (Supplementary
Fig. 6A-F). To test if complete abrogation of p53 in defective
cells led to a more dramatic rescue of their elimination, we
generated Bmpr1a−/−; p53−/− cells using CRISPR (Supple-
mentary Fig. 6G). We found that the deletion of p53 completely
rescued both mTOR levels and the elimination of BMP-
defective cells in competition with wild-type cells (Fig. 4g–i).
These results indicate that p53 lies upstream of mTOR during
defective cell elimination by cell competition.
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P53 and mTOR signalling determine cell competition in vivo.
To address the in vivo signiﬁcance of our observations, we ﬁrst
analysed tetraploid chimeras. Tetraploid embryos are viable until
very late in gestation21–23, but we and others have previously
shown that at 6.5 dpc 4n cells are efﬁciently eliminated in chi-
meras with 2n cells12,32. When we analysed levels of mTOR
activity in 4n cells in chimeras at 5.0 dpc, just prior to the stage at
which they are eliminated, we found that they display a loss of
mTOR activity (Fig. 5a and Supplementary Fig. 7A). This indi-
cated that defective cells also lose mTOR activity prior to their
elimination in the embryo. We then tested if hyperactivation of
the mTOR pathway is sufﬁcient to rescue defective cell elimina-
tion in vivo. Injection of 4n-Tsc2−/− ESCs into diploid embryos
gave rise to high contribution chimeras that sustained high
mTOR activity (Fig. 5a, b and Supplementary Fig. 7B, C). Sig-
niﬁcantly, while at 6.5 dpc, 71% of 4n cells in chimeras are
apoptotic, only 7% of 4n-Tsc2−/− cells in chimeras were apoptotic
(n= 5; Fig. 5c)12. Furthermore, in 43% of embryos these epiblast
cells deformed the epithelial bilayer and overgrew into the pro-
amniotic cavity (n= 7; Fig. 5b, d), suggesting that the persistence
of 4n cells was disrupting embryonic development. In chimeras
with diploid cells, 4n cells rarely survive past gastrulation32.
However, we observed that 4n-Tsc2−/− cells gave rise to highly
chimeric embryos at 7.5 dpc and 9.0 dpc (Fig. 5d, e). In spite of
their survival, at 9.0 dpc these embryos suffered a strong devel-
opmental delay and presented an abnormal epithelial organisa-
tion when compared to their littermates, either because of the
negative effects of constitutive mTOR activation on development
or because of the negative consequences that the persistence of
tetraploid cells has on embryogenesis.
The above results indicated that repression of mTOR signalling
leads to defective cell elimination during early mouse develop-
ment and led us to investigate the frequency of this occurrence
during normal development. For this we analysed pS6 levels in
embryos cultured either in DMSO or with pan-caspase inhibitors
for 16–18 h from 5.5 to 6.25 dpc. This treatment completely
abolished TUNEL-positive apoptotic cells and led to a 35%
increase in epiblast cell number (Fig. 6a–c). In cells, caspase
inhibition results in an accumulation of Bmpr1a−/− cells with low
mTOR pathway activity (Fig. 2a–c). Similarly, we observed in vivo
that while in control embryos few cells (~3%) showed loss of
pS6S240/244, in embryos treated with the pan-caspase inhibitor
there was a signiﬁcant increase in the proportion of pS6S240/244-
negative cells, with about 42% of cells showing low or no staining
for this mTOR activation marker (Fig. 6d, e and Supplementary
Fig. 8A). Analysis of total S6 levels revealed that those cells that
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had down-regulated pS6 expression showed robust total
levels of S6 protein in the epiblast (Fig. 6f, g and Supplementary
Fig. 8B, C), conﬁrming that the loss of mTOR signalling occurring
in those cells fated for elimination is not due to a general decrease
in protein expression. These results suggest that during early
post-implantation development a rapid ﬂux of cell competition
eliminates around 35% of cells, and that this elimination likely
occurs through repression of mTOR pathway activity.
We next analysed if p53 could also be upstream of mTOR in
the embryo. At 5.5 dpc p53 expression is heterogeneous, with a
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small proportion of cells showing elevated p53 expression
(Fig. 6h). Analysis of the relative p53 and pS6 levels in 5.5 dpc
embryos failed to reveal any correlation between the expression of
these factors in the unperturbed embryo (Supplementary Fig. 8D).
One likely explanation for this is that p53 has a very short half-life
and its expression oscillates, with apoptosis being induced only
when protein levels are stabilised above a certain threshold33,34.
Furthermore, how quickly p53 levels increase in the cell also
determines if apoptosis is induced or not35. For these reasons, to
obtain a rapid stabilisation of p53 and analyse how this affects
mTOR activity, we have used the Mdm2 inhibitor Nutlin-3a.
When 6.5 dpc embryos were cultured in the presence of Nutlin-3a
for 6 h we observed a direct correlation at the single-cell level
between p53 and pS6 levels (Fig. 6i, j). This suggests that in the
embryo, sustained p53 expression is required to repress mTOR.
These observations together with the ﬁndings that mutation of
p53 in 4n cells allows these to give rise to very high chimeras that
survive till birth36, indicate that during early embryogenesis both
p53 and mTOR signalling play key roles in defective cell
elimination, and strongly suggest that p53 acts upstream of
mTOR during this process.
Discussion
Cell competition is thought to act as a quality control mechanism
and has primarily been studied in ﬂies. More recently, ﬁtness
selection though cell competition has been shown in the early
mammalian embryo at the onset of gastrulation12,13. However,
the mechanisms marking cells as less ﬁt and those involved in
loser cell elimination have remained obscure. Here we start to
unravel these mechanisms with three key ﬁndings. First that two
cell types with very different types of defects (mispatterned and
karyotypically abnormal cells) are eliminated via mTOR-
dependent cell competition. Second, in both genetic circuits, the
tumour suppressor p53 operates upstream of mTOR as an
essential regulator of kinase activity. Third, this epistatic rela-
tionship between mTOR and p53 was substantiated not only in
cultured ESCs, but also in mouse embryos at the onset of
gastrulation.
Little is known about mTOR and cell competition. In Droso-
phila, increasing insulin signalling (an upstream mTOR reg-
ulator) by expression of the catalytic subunit of PI3K3 or
mutation of Pten37 is not sufﬁcient for cells to acquire a winner
status and eliminate the surrounding wild-type cells. Similarly
Tsc1, Tsc2 or Pten mutations do not rescue the elimination of
Minute cells in imaginal wing discs38. In contrast to these
observations, here we ﬁnd two things. First, that two cell types
with very different types of defects, such as BMP defective and
tetraploid are eliminated by mTOR repression. Second, that
increasing mTOR activity by Tsc2 mutation makes cells into
super-competitors that can eliminate wild-type cells. Together,
these results point to the relative levels of mTOR signalling as
being a key determinant of the competitive nature of cells during
early embryogenesis. Our ﬁnding that blocking apoptosis in the
embryo results in the accumulation of cells with low mTOR
activity from ~1% to ~40%, strengthens the importance of these
ﬁndings, as they suggest that competition through mTOR is not
just a sporadic effect, but occurs at a signiﬁcant scale during early
post-implantation development.
Our studies also reveal that during mouse cell competition
mTOR is regulated by p53. P53 is emerging as a key player in cell
competition in different systems. In ﬂies p53 is required to sustain
the metabolic status of winner cells during competition, as well as
for their ability to signal loser cell elimination29. In mammals the
roles of p53 in cell competition appear to be different. The
observations that polarity deﬁcient MDCK cells30, as well as BMP
defective and tetraploid mouse ESCs, have a non-lethal increase
in p53 independently of being in a competitive context suggests
that a moderate increase in p53 occurs in response to a wide
variety of stresses and acts as a less-ﬁt signature. This signature
does not directly affect viability, but instead labels cells as losers
when placed in a competitive environment with wild-type cells, as
we have found in the mouse embryo with BMPR-defective and
tetraploid cells, or as others have observed through mutation of
Mdm2/415, in haematopoetic stem/progenitor cells subject to
DNA damage31 or in polarity defective MDCK cells30.
The pathways acting downstream of p53 during cell competi-
tion have so far remained elusive, and here by identifying mTOR
we gain insight into the molecular mechanisms used by p53 to
determine relative cell ﬁtness. Given our data, we envisage two
possible scenarios to explain the relationship between p53 and
mTOR. First, it is possible that p53 elevation labels defective cells
as losers, but when these cells are in a competitive environment a
second unidentiﬁed factor becomes activated in these defective
cells, and this mediates repression of mTOR and their elimina-
tion. Alternatively it is possible that during competition, p53
changes in activity to repress mTOR and induce defective cell
elimination. Distinguishing between these possibilities will help
elucidate if the interaction between p53 and mTOR is direct or
not.
Cell competition has been proposed to have roles from the
elimination of defective cells in development to promoting the
expansion of cancer cells during tumourigenesis39. However, the
roles of cell competition during mouse development remain
unresolved. The recent observation that the low c-Myc cells
eliminated by cell competition are of a lower pluripotency status
(primed pluripotent), than their high c-Myc counterparts (that
are naive pluripotent) has led to the interesting proposal that cell
competition is acting to remove cells that exit naive pluripotency
prematurely16. However, it is important to deﬁne precisely at
which developmental stage this removal is likely to be occurring.
During early mouse embryogenesis, there are two waves of cell
death that take place, one at the pre-implantation stage, at about
4.5 dpc18 and a second during early post-implantation develop-
ment, at 6.5 dpc40. At 4.5 dpc, epiblast cells are in the naive
pluripotent state; therefore, it is plausible to argue that the wave
of apoptosis occurring at this stage is removing cells that have
acquired the primed pluripotent state precociously. In contrast to
this, at 5.5 dpc in the early post-implantation embryo, all cells are
uniformly primed pluripotent41,42 and then at 6.5 dpc and 7.5 dpc
these cell initiate gastrulation in an asynchronous fashion8. This
makes it less likely that those cells dying at 6.5 pc are doing so
because they have acquired a primed pluripotency status before
their neighbours.
The scale of changes occurring during the onset of differ-
entiation, including a doubling of the proliferation rate43, means
there is a signiﬁcant potential for the emergence of defective cells.
Therefore, an alternative possibility is that the cell elimination
occurring at 6.5 dpc is because cell competition is acting as a
quality control checkpoint to prevent these cells from con-
tributing to the germline, that is speciﬁed around this time44. One
prime example of a cell type that could be eliminated by this
mechanism is karyotypically abnormal cells. These are remark-
ably common in early mammalian development, for example in
humans 50–80% of embryos have karyotypically abnormal cells at
pre-implantation stages19. However, karyotypic abnormalities are
not necessarily per se prohibitive for early embryonic develop-
ment, as even fully tetraploid embryos are viable until very late in
gestation21–23 and they gastrulate at the same time as wild-type
embryos45. Here we show that cell competition eliminates these
tetraploid cells in a mTOR dependent manner at 6.5 dpc, just
when the germline is being speciﬁed44. The observation that
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-04167-y ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:1763 | DOI: 10.1038/s41467-018-04167-y |www.nature.com/naturecommunications 9
mutation of p53 allows tetraploid cells to give rise to high chi-
meras that survive till birth36, strengthens the case for the
involvement of p53-mTOR signalling in the elimination tetra-
ploid cells. Therefore, together, these results suggest cell compe-
tition may be an important checkpoint for the removal of
karyotypically abnormal cells acting before the germline forms to
ensure its integrity.
A third possible role for cell competition during early mouse
embryogenesis is in the regulation of embryo size. The mouse
embryo is remarkably regulative and can compensate for a sig-
niﬁcant gain or loss of cells. For example, the embryo adjusts to a
doubling in cell number at pre-implantation stages46 or a loss of
up to 90% of cells at early post-implantation stages47 and reg-
ulates growth so that by organogenesis embryo size is similar to
that of untreated controls. It is possible that by balancing pro-
liferation and cell death, cell competition may coordinate the
growth of the rapidly expanding early post-implantation mouse
embryo8, and in this way contribute to this regulative ability of
the early mouse embryo. The fact that mTOR is a major meta-
bolic regulator raises the possibility that through p53-mTOR-
regulated cell competition, the epiblast cells may be able to
integrate nutrient and growth factor inputs and adjust cell
numbers to ensure that the rapid acceleration of embryonic
proliferation remains within speciﬁc parameters. The observation
that treating pre-implantation embryos with insulin-like growth
factor 1, that is upstream of mTOR, leads to larger embryos by
increasing inner cell mass cell numbers48, is tantalising evidence
to suggest that cell competition may indeed play this role.
Tsc2 null mice die between 9.5 and 12.5 dpc49,50. In contrast to
this, p53 null mice survive until adult-hood51, but both p63 and
p73 can compensate for its function during early post-
implantation development52. c-Myc is another important reg-
ulator of cell competition, and although null mutants die around
10.5 dpc53,54, d-Myc can also compensate for c-Myc function
during early mouse development55. To help uncover the roles of
cell competition it will be important to ascertain the levels of cell
death in the above mutant strains, and if reduced, to establish the
identity of the cells that would normally have been eliminated. In
parallel, it will also be interesting to test if mouse mutants for
Tsc2, the p53 family or the Myc family can scale properly.
In conclusion, our work has uncovered that p53 regulation of
mTOR is an important determinant of cellular ﬁtness during
early mammalian embryonic development. The fact that an
increase or a decrease in expression of either of these signals
induces defective cell elimination or super-competition just
highlights this importance. It will be fascinating to uncover how
conserved this pathway is in other mammalian tissues, as well as
to understand if it plays any role in the ﬂy.
Methods
Cell culture. Wild-type E14 cells were a gift from Prof. A. Smith; Bmpr1a−/− cells
and tetraploid cells were obtained from previously described sources12,20. No cell
lines used here are listed in the ICLAC and NCBI Biosample database of commonly
misidentiﬁed cell lines.
Cells were cultured at 37 °C and 5% CO2 in GMEM-BHK1 supplemented with
10% FCS, 2 mM glutamine, 1 ×MEM non-essential amino acids, 1 mM sodium
pyruvate, 0.1 mM β-mercaptoethanol (all Thermo Fisher Scientiﬁc) and 100 units/
ml leukaemia inhibitory factor (generated and tested in the lab). ESCs were
maintained on gelatin-coated ﬂasks and media was changed daily. Cell lines were
routinely tested for mycoplasma contamination.
Details of rapamycin (Cayman Chemical), Nutlin-3a (BioVision) and caspase
inhibitor (Z-VAD-FMK, R&D Systems) treatments are outlined in ﬁgure legends.
Competition assay. Cells were seeded onto plates coated with ﬁbronectin (Merck)
at a concentration of 2.05 × 104 cells/cm2 either separately or mixed for co-cultures
at a 50:50 ratio. The cells were cultured in N2B27 media (Neurobasal media;
DMEM F12 media; 0.5 × B27 supplement; 0.5 × N2 supplement; 0.1 mM
2-mercaptoethanol; 2 mM glutamine; all Thermo Fisher Scientiﬁc) to allow for
differentiation. At the indicated time-points, the cells were counted using ViCell
Counter and Viability Analyser (Beckman Coulter) and proportions of each cell
type in co-cultures were determined using LSR II Flow Cytometer (BD Bioscience).
Sytox blue (Thermo Fisher Scientiﬁc) or propidium iodide (Sigma) was used to
stain for dead cells.
Mice. All mice were maintained on a 10 hr–14 hr light–dark cycle and were
maintained and treated in accordance with the Home Ofﬁce’s Animals (Scientiﬁc
Procedures) Act 1986. Wild-type mice analysed were on a CD1 out-bred genetic
background. Noon of the day of ﬁnding a vaginal plug was designated 0.5 dpc/.
Embryo dissection was performed M2 media (Sigma). No distinction was made
between male and female embryos during the analysis.
Chimeras. Embryos were harvested from F1 (C57BL/6 × CBA) or C57BL/6 × F1
crosses. 2.5 dpc embryos were ﬂushed from oviducts in M2 (Sigma) and cultured in
BlastAssist (Origio) under embryo-tested mineral oil (Sigma) at 37 °C and 7% CO2
in air. ESCs (3–8) were injected via a laser-generated perforation in the zona
pellucida using XYClone (Hamilton Thorne Biosciences).
Embryo culture. For caspase inhibitor experiments, embryos were dissected at 5.5
dpc, cultured overnight (18 h) at 37 °C and 5% CO2 in 200 μM pan-caspase inhi-
bitor Z-VAD-FMK (R&D Systems) or the equivalent DMSO volume in poor
N2B27 media (Neurobasal media; DMEM F12 media; 0.25 × B27 supplement;
0.25 × N-2 supplement; 0.1 mM 2-mercaptoethanol; 2 mM glutamine; all Thermo
Fisher Scientiﬁc), and ﬁxed as below. For Nutlin-3a experiments, embryos were
dissected at 6.5 dpc, cultured in 10 or 20 μM Nutlin-3a (BioVision) or the
equivalent DMSO volume for 6 h in poor N2B27 media, and ﬁxed.
Immunoﬂuorescence. Cells were ﬁxed in 4% PFA for 10 min, permeabilised with
0.4% Triton X-100 for 5 min and blocked with 10% BSA (Sigma), 0.1% Triton
X-100 for 1 h. Staining with primary antibodies (pS6S240/244 #5264, S6 #2317, p53
#2524, cleaved caspase-3 #9664, all Cell Signaling; and λH2AX, Millipore 05-636;
all 1:200 dilution) was performed overnight at 4 °C in 1% BSA, 0.1% Triton X-100.
After three washes in PBS, secondary antibodies (Alexaﬂuor-488, 546 or 633,
Thermo Fisher Scientiﬁc; 1:500 dilution) and Hoescht (Thermo Fisher Scientiﬁc;
1:1000 dilution) were applied for 1 h. Coverslips were then mounted on glass slides
using Vectashield (Vector Labs).
The embryos were ﬁxed using 4% PFA in PBS+ 0.01% Triton X-100 and 0.1%
Tween. Permeabilisation was performed with 0.5% Triton X-100 in PBS for 20 min,
and embryos were blocked using 2% horse serum in PBS+ 0.1% Triton X-100
(PBT) for 45 min. Primary antibodies, as above, were incubated with embryos in
blocking solution overnight at 4 °C. Following three washes in PBT, the embryos
were incubated with secondary antibodies and Hoescht, as above, for 1 h at 4 °C.
TUNEL staining was performed using Click-iT Plus TUNEL Assay (Thermo Fisher
Scientiﬁc). All images were captured on a Zeiss LSM-780 confocal microscope.
Embryo cryosectioning was performed by soaking ﬁxed (4% paraformaldehyde
for 6 h at 4 °C) embryos ﬁrst in 30% sucrose/PBS at 4 °C and then in 7.5% gelatin/
15% sucrose/PBS at 37 °C, before being transferred to room temperature to allow
the gelatin/sucrose mixture to solidify and blocks to form. Blocks were transferred
to 2-methylbutane at -70 °C and stored at −80 °C before sectioning. Sectioning was
performed on a cryostat (Leica) using glass blades. GFP was detected using anti-
GFP antibody #A-31851 (Thermo Fisher Scientiﬁc, 1:50 dilution).
In cells, the levels of cytoplasmic pS6 per ﬁeld were quantiﬁed by measuring
average ﬂuorescence intensity in the two pixels surrounding cell nuclei, using
Hoescht staining as a mask. Levels of nuclear p53 per ﬁeld were quantiﬁed by
measuring average ﬂuorescence intensity in cell nuclei, using Hoescht staining as a
mask. This was performed in ImageJ on single sections. In both cases, a minimum
of three ﬁelds were quantiﬁed in each experiment.
For pS6 and p53 quantiﬁcation in embryos, a line was drawn manually across
the nucleus and basal cytoplasm of each cell and the maximum ﬂuorescence
intensity across each line was measured. To deﬁne low pS6, a cut-off of 20 000 grey
values (litter 1; n= 9), 12,000 grey values (litter 2; n= 9) or 10 000 grey values
(litter 3; n= 10) was used to deﬁne low pS6. We adjusted the cutoff between litters
owing to variability in mean ﬂuorescence levels between independent experiments.
A ratio cut-off of 0.3 was used to deﬁne the low pS6:S6 population. Example graphs
showing the cut-off used are presented in Supplementary Fig. 8A-B. For cleaved
caspase-3 quantiﬁcation of tetraploid cells in embryos, cells positive or negative for
cleaved caspase-3 were counted manually. In all cases, the analysis was performed
in ImageJ on single sections.
Flow cytometry staining. Cells were detached from plates using accutase (Sigma)
and ﬁxed in 7.4% formaldehyde in N2B27 media for 10 min. Permeabilisation was
carried out using ice-cold methanol, and cells were blocked using 1% BSA. The
primary antibody (pS6240/244 #5264, cleaved caspase-3 #9664, both Cell Signaling;
1:200 dilution) was incubated with cells for 1 h at room temperature. After
washing, the secondary antibody was applied (Alexaﬂuor-546/405, Thermo Fisher
Scientiﬁc; 1:2000 dilution) for 30 min. CD31 (BD Biosciences, MEC13.3; 1:200
dilution) staining was performed on live cells. The antibody was incubated with
cells for 45 min at 4 °C and cells were washed in PBS prior to ﬂow cytometry
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analysis. All ﬂow cytometry was performed using a BD LSR II ﬂow cytometer and
analysed using FlowJo software (both BD Biosciences).
Western blotting. Cells lysates were collected using Laemmli buffer (0.05 M Tris-
HCl at pH 6.8, 1% SDS, 10% glycerol, 0.1% β-mercaptoethanol), quantiﬁed using
BCA quantiﬁcation (Thermo Fisher Scientiﬁc) and resolved using Criterion XT
pre-cast gels (BioRad) followed by transfer to PVDF membranes. Antibodies used
are as follows: pS6S240/244 #5264, S6 #2317, p53 #2524, p4E-BP1T37/46 #2855, total
4E-BP1 #9644, cleaved caspase-3 #9664, cleaved PARP #9544, pAKTT473 #4060,
TSC2 #4308, β-actin #4970; all from Cell Signaling Technology and used at 1:1000
dilutions. All uncropped western blots can be found in Supplementary Fig. 9.
Molecular biology. Total RNA was isolated using RNeasy (Qiagen) from three
independent experiments. Labelling and hybridisation to the mouse Gene 1.0 ST
Array system (Affymetrix), as well as data acquisition was performed by UCL
Genomics at the Institute of Child Health. Normalisation and statistical analysis of
the resulting array data was performed using GeneSpring software. Microarray data
was also analysed by moderated t-test implemented by limma R package software56
and a p-value cut-off of 0.05 was assigned for input into IPA.
Total cell mRNA was extracted using RNeasy (Qiagen). cDNA was synthesised
using Superscript III reverse transcriptase (Invitrogen), and SYBR Green Master
Mix (Qiagen) was used for qPCR reaction. The following primers were used: Nanog
F, CTTACAAGGGTCTGCTACTGAGATGC; Nanog R, TGCTTCCTGGCAAGG
ACCTT; Esrrb F, AACCGAATGTCGTCCGAAGAC; Esrrb R, GTGGCTGAGGG
CATCAATG; Rex1 F, CGAGTGGCAGTTTCTTCTTGG; Rex1 R, GACTCACTT
CCAGGGGGCAC; Klf4 F, ACCTATACCAAGAGTTCTCATC; Klf4 R, TCTGGC
ACTGAAAGGGCCGG; p21 F CCTGTCACTGTCTTGTACCCT; p21 R, GCGTT
TGGAGTGGTAGAAATCT; p53 F CACGTACTCTCCTCCCCTCAAT; p53 R
AACTGCACAGGGCACGTCTT; beta-actin F, CTAAGGCCAACCGTGAAAAG;
and beta-actin R, ACCAGAGGCATACAGGGACA.
To generate p53 null CRISPR lines, a p53 guide (5′-GCAGACTTTTCGCCACA
GCG was cloned into lentiCRISPRv2 plasmid. Viruses were generated by transfecting
this plasmid along with helper plasmids VSV-G and psPAX2 into HEK293T
packaging cells. After 48 h, the media from these cells was applied to ESCs with 4ug/
ml polybrene. Two rounds of infection, for 4 h and then overnight, were carried out.
The cells were then selected using 2 μg/ml puromycin and plated at single-cell
conﬂuency. Clones were screened for loss of p53 protein by western blot.
To generate Tsc2 null CRISPR lines, we designed guide RNAs targeting its GAP
domain, disruption of which has been previously reported to result in loss of
protein57. To generate tetraploid mutant lines, we ﬁrst infected cells with lentiCas9-
Blast, as before, and selected a Cas9-expressing clone using Blasticidin treatment
(at 2 μg/ml). This was infected with pU6-sgRNA-EF1alpha-hygro, in which we
cloned the gRNA 5′GACAAGAAACGGCACCT. The lentiCas9-Blast was a gift
from Feng Zhang (Addgene plasmid # 52962) and the pU6-sgRNA EF1Alpha-
puro-T2A-BFP was a gift from Jonathan Weissman (Addgene plasmid #60955),
and modiﬁed to hygro by Matias de Vas, Imperial College London. Clones selected
with hygromycin (150 μg/ml) were screened on western blot for loss of Tsc2. To
generate Tsc2−/− clones in wild-type cells, we co-transfected: hCas9; gRNAs (5′
GAAGGCCGGCCTACCTCATT and 5′GCATGGCTCTTACAGGTACA) using
gRNA cloning vector (both a gift from George Church; Addgene number #41824);
and a hygromycin marker (Clontech). The cells were selected using hygromycin.
Retroviral infections were performed as described above. All shRNAs (TSC2 #1,
AGCTGTTACCTTGACGAAT; TSC2 #2, TGGACTACAAGTGCAACCT; PTEN,
CAGCTAAAGGTGAAGATAT) were cloned into a MSCV-miRE-IRES-GFP-puro
vector, which was a kind gift from Johannes Zuber (IMP, Vienna, Austria).
Statistical methods. Statistical analysis was performed using GraphPad Prism
software. Statistical methods used are indicated in the relevant ﬁgure legends. No
randomisation or blinding was used in experiments. Sample sizes were selected
based on the observed effects and listed in the ﬁgure legends.
Data availability. The raw data for wild-type and Bmpr1a mutant cells in separate
culture and co-culture after three days in N2B27 have been deposited in the GEO
database under accession code GSE109494. The authors declare that all data sup-
porting the ﬁndings of this study are available within the article and its supple-
mentary information ﬁles or from the corresponding author upon reasonable request.
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